ClinConnect ClinConnect Logo
Search / Trial NCT00271622

The Neurodevelopmental and Behavioral Phenotyping Screening Protocol

Launched by NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH) · Dec 31, 2005

Trial Information

Current as of July 09, 2025

Recruiting

Keywords

Developmental Delay Pediatric Pervasive Developmental Disorder Early Development Healthy Control Subjects Autism Spectrum Disorders Healthy Volunteer Hv

ClinConnect Summary

The Neurodevelopmental and Behavioral Phenotyping Screening Protocol is a clinical trial aimed at understanding more about neurologic disorders, autism, and related conditions. The study is looking for healthy volunteers as well as individuals who may be at risk for psychiatric or neurodevelopmental disorders, particularly autism spectrum disorder. This trial is currently recruiting participants of all ages starting from 6 weeks old. To participate, subjects or their parents must be able to understand the study and provide written consent.

Participants can expect to undergo a thorough evaluation, which may include interviews and various medical tests. These tests could check brain function, overall health, and the presence of certain substances in the body. It's important to note that for children, consent must be obtained from all legal guardians, ensuring everyone involved agrees to the child's participation. This study is a valuable opportunity to contribute to research that could improve our understanding of these complex conditions.

Gender

ALL

Eligibility criteria

  • * INCLUSION CRITERIA:
  • Subjects must be at least 6 weeks of age.
  • Subjects or their parents must be competent to comprehend the purpose of the screening process and to provide written informed consent. Parents/guardians will sign the consent form, and both minors and adults (depending on results of capacity assessment) will be asked to assent only if it is determined that they understand their role in the study.
  • Subjects must be willing to undergo an evaluation which may include a psychiatric interview; and medical, neurological, and laboratory examinations (as appropriate, such as renal and liver function tests, serum electrolytes, urinalysis, blood levels of psychotropic drugs, and urine drug screen for the presence of psychoactive drugs and drugs of abuse, as determined on a subject-to-subject basis).
  • EXCLUSION CRITERIA:
  • -Lack of appropriate consent: For minor patients, consent must be obtained from all legal guardians/caretakers, including both parents in separated or divorced families where there is shared legal custody of the child. In such cases, both parents must consent to the child s participation in this protocol.

About National Institute Of Mental Health (Nimh)

The National Institute of Mental Health (NIMH) is a leading federal agency dedicated to advancing the understanding and treatment of mental health disorders through innovative research and clinical trials. As part of the National Institutes of Health (NIH), NIMH focuses on a broad spectrum of mental health issues, including mood disorders, anxiety disorders, schizophrenia, and developmental disorders. By fostering collaboration among researchers, clinicians, and the community, NIMH aims to translate scientific discoveries into effective interventions and improve mental health outcomes for individuals across the lifespan. Through its commitment to rigorous research methodologies and ethical standards, NIMH plays a pivotal role in shaping the future of mental health care and policy.

Locations

Bethesda, Maryland, United States

Patients applied

0 patients applied

Trial Officials

Genalynne C Mooneyham, M.D.

Principal Investigator

National Institute of Mental Health (NIMH)

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials